Robert W. Baird initiated coverage on Renovacor with a new price target
$RCOR
Biotechnology: Pharmaceutical Preparations
Health Care
Robert W. Baird initiated coverage of Renovacor with a rating of Outperform and set a new price target of $9.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/13/2022 | $9.00 | Outperform | Robert W. Baird |
| 10/14/2021 | $22.00 | Buy | Ladenburg Thalmann |
| 10/1/2021 | $20.00 | Buy | Chardan Capital Markets |
15-12G - Renovacor, Inc. (0001799850) (Filer)
EFFECT - Renovacor, Inc. (0001799850) (Filer)
EFFECT - Renovacor, Inc. (0001799850) (Filer)
4 - Renovacor, Inc. (0001799850) (Issuer)
4 - Renovacor, Inc. (0001799850) (Issuer)
4 - Renovacor, Inc. (0001799850) (Issuer)
Rocket Pharmaceuticals (NASDAQ:RCKT) has announced an acquisition of Renovacor (AMEX:RCOR) that is expected to be completed in Q1 of 2023. Under the terms of the agreement, Rocket Pharmaceuticals has agreed to give Renovacor $53.00 million in stock in exchange for RCOR stock. About The Companies Involved Rocket Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. Renovacor Inc is a preclinical stage gene therapy company developing a pipeline of innovative and proprietary AAV-based gene therapies for BAG3 gene mutation-associated diseases in areas of high unmet medical need. Its t
Upgrades For Berkshire Hathaway Inc (NYSE:BRK), Edward Jones upgraded the previous rating of Hold to Buy. Berkshire Hathaway earned $6312.49 in the second quarter, compared to $4399.91 in the year-ago quarter. For Aurora Cannabis Inc (NASDAQ:ACB), Canaccord Genuity upgraded the previous rating of Sell to Hold. For the fourth quarter, Aurora Cannabis had an EPS of $0.00, compared to year-ago quarter EPS of $0.55. At the moment, the stock has a 52-week-high of $6.05 and a 52-week-low of $1.21. Aurora Cannabis closed at $1.40 at the end of the last trading period. According to Exane BNP Paribas, the prior rating for TechnipFMC PLC (NYSE:FTI) was changed from Neutral to Outperform. In the s
BTIG analyst Yun Zhong downgrades Renovacor (AMEX:RCOR) from Buy to Neutral.
SC 13D/A - Renovacor, Inc. (0001799850) (Subject)
SC 13G/A - Renovacor, Inc. (0001799850) (Subject)
SC 13D - Renovacor, Inc. (0001799850) (Subject)
Brings more than 20 years of experience as an entrepreneur scientist, CEO, operator, investor, and board member of public and private biopharmaceutical companies Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that the Company appointed Joan Lau, Ph.D. to its board of directors. Dr. Lau's appointment increases Rockwell Medical's board of directors to seven members. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231017906241/en/RMTI) (Photo: Business Wire)"
Dr. Dhanasekharan joins Renovacor with extensive experience overseeing development, manufacturing and supply operations for biologics including AAV gene therapies Renovacor, Inc. (NYSE:RCOR), a biotechnology company developing adeno-associated virus (AAV)‑based gene therapies for devastating cardiovascular and central nervous system diseases resulting from BAG3 gene variants, today announced the appointment of Kumar Dhanasekharan, Ph.D., as Senior Vice President of Technical Operations. "With Kumar's appointment, we've added yet another innovative industry expert to Renovacor's diverse and growing leadership team," said Magdalene Cook, M.D., Chief Executive Officer of Renovacor. "Kumar is
Dr. Shin to help advance REN-001 into the clinic by leveraging nearly two decades of expertise in clinical development, academic research and medical practice Renovacor, Inc. (NYSE:RCOR), an early-stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for devastating cardiovascular and central nervous system diseases resulting from BAG3 gene variants, today announced the appointment of Jordan Shin, M.D., Ph.D., as Senior Vice President of Clinical Development and Translational Science. "We are excited to welcome Jordan to Renovacor's leadership team during this pivotal time for the company," said Magdalene Cook, M.D., Chief Executive Officer of Renovacor.
Brings more than 20 years of experience as an entrepreneur scientist, CEO, operator, investor, and board member of public and private biopharmaceutical companies Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that the Company appointed Joan Lau, Ph.D. to its board of directors. Dr. Lau's appointment increases Rockwell Medical's board of directors to seven members. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231017906241/en/RMTI) (Photo: Business Wire)"
Acquisition further extends Rocket's leadership in AAV-based cardiac gene therapy and expands focus and capabilities to BAG3-associated dilated cardiomyopathy Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders with high unmet need, today announces that it has completed the previously announced acquisition of Renovacor, Inc. (NYSE:RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases. Under the terms of t
Acquisition further strengthens Rocket's leadership in AAV-based cardiac gene therapy and expands Company's near-term clinical assets for the treatment of heart conditions Significant unmet medical need in BAG3-associated dilated cardiomyopathy, with meaningful commercial opportunity, comparable to Danon Disease Creates strong synergies by combining key assets, personnel, capabilities and IP, as well as access to world-leading scientific and clinical collaborators, expected to deliver long-term value for Rocket and Renovacor shareholders We believe compelling preclinical data generated by Renovacor validates mechanism of action of AAV-based transgene replacement strategy for BAG-3 di
Robert W. Baird initiated coverage of Renovacor with a rating of Outperform and set a new price target of $9.00
Ladenburg Thalmann initiated coverage of Renovacor with a rating of Buy and set a new price target of $22.00
Chardan Capital Markets initiated coverage of Renovacor with a rating of Buy and set a new price target of $20.00